Skip to content
BHP

Tirzepatide

Mounjaro · Zepbound · LY3298176

Reviewed by the BestHealingPeptides Editorial Team ·

On this page

What is tirzepatide, and is it a peptide?

Tirzepatide is a peptide medicine: an amino acid sequence with a C20 fatty diacid moiety that enables albumin binding, acting as an agonist at both the GIP and GLP-1 receptors. In the UK it is the active substance of Mounjaro (KwikPen), a prescription only medicine for type 2 diabetes (adults, adolescents and children aged 10 years and above) and for weight management in adults.

Sources: Mounjaro KwikPen SmPC (emc)

Sourced facts at a glance

  • Mechanism and half-life: A long-acting GIP and GLP-1 receptor agonist; its activity on the GIP receptor is similar to native GIP, and on the GLP-1 receptor lower than native GLP-1. Elimination half-life approximately 5 days, 99% bound to plasma albumin, steady-state exposure after 4 weeks. (Mounjaro KwikPen SmPC (emc))
  • UK brand and licensed indications: Mounjaro KwikPen (2.5, 5, 7.5, 10, 12.5 and 15 mg) is a prescription only medicine. It is indicated for insufficiently controlled type 2 diabetes mellitus in adults, adolescents and children aged 10 years and above, as an adjunct to diet and exercise (monotherapy when metformin is considered inappropriate, or in addition to other diabetes medicines), and for weight management in adults, with a reduced-calorie diet and increased physical activity, with an initial BMI of 30 kg/m2 or more, or 27 to under 30 kg/m2 with at least one weight-related comorbid condition. (Mounjaro KwikPen SmPC (emc))
  • UK authorisation dates: The MHRA authorised a weight-management indication for Mounjaro on 8 November 2023 (national application route) and approved the four-dose KwikPen on 25 January 2024; the KwikPen SmPC gives 25 January 2024 as its date of first authorisation. (MHRA, 8 November 2023; MHRA, 25 January 2024; Mounjaro KwikPen SmPC (emc))
  • NICE guidance: TA924 (type 2 diabetes, published 25 October 2023) and TA1026 (overweight and obesity, published 23 December 2024; adults with an initial BMI of at least 35 kg/m2, usually 2.5 kg/m2 lower for some ethnic backgrounds, and at least 1 weight-related comorbidity) recommend tirzepatide only within defined criteria and commercial arrangements. (NICE TA924; NICE TA1026)
  • Weight-management trial result (SURMOUNT-5): In 751 adults with obesity without diabetes in an open-label phase 3b trial, mean body-weight change at 72 weeks was -20.2% with tirzepatide (maximum tolerated dose 10 or 15 mg weekly) versus -13.7% with semaglutide (1.7 or 2.4 mg weekly). (Aronne et al., NEJM 2025 (PMID 40353578))
  • Cardiovascular outcomes trial (SURPASS-CVOT): In 13,299 randomised adults with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was non-inferior to dulaglutide for the primary composite of cardiovascular death, myocardial infarction or stroke (hazard ratio 0.92; 95.3% CI 0.83 to 1.01); superiority was not shown. (Nicholls et al., NEJM 2025 (PMID 41406444))

A dual GIP and GLP-1 receptor agonist: an amino acid sequence with a C20 fatty diacid moiety that enables albumin binding, giving an elimination half-life of approximately 5 days and once-weekly subcutaneous dosing. Licensed in the UK as Mounjaro (KwikPen), a prescription only medicine for type 2 diabetes in adults, adolescents and children aged 10 years and above and for weight management in adults (Zepbound is the US brand only). In the head-to-head SURPASS-2 and SURMOUNT-5 trials tirzepatide produced greater HbA1c reduction and weight loss than semaglutide.

Mechanism of action

Tirzepatide is a long-acting agonist of both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor (UK SmPC section 5.1). Both receptors are present on pancreatic alpha and beta endocrine cells, heart, vasculature, immune cells (leukocytes), gut and kidney, and GIP receptors are also present on adipocytes. The SmPC describes tirzepatide as highly selective for the human GIP and GLP-1 receptors, with high affinity for both. Its activity on the GIP receptor is similar to that of native GIP hormone, while its activity on the GLP-1 receptor is lower than that of native GLP-1 hormone.

Tirzepatide is an amino acid sequence with a C20 fatty diacid moiety that enables albumin binding and prolongs half-life (SmPC section 5.2). It is metabolised by proteolytic cleavage of the peptide backbone, beta-oxidation of the C20 fatty diacid moiety and amide hydrolysis.

On glycaemic control, the SmPC states that tirzepatide increases pancreatic beta-cell glucose sensitivity and enhances first- and second-phase insulin secretion in a glucose-dependent manner. It also delays gastric emptying, which may slow post-meal glucose absorption; the SmPC notes that this delay diminishes over time.

On appetite and body weight, the SmPC notes that GIP and GLP-1 receptors are expressed in brain areas important to appetite regulation, and that animal studies show tirzepatide distributes to and activates neurons in brain regions involved in regulating appetite and food intake. Clinical studies show it reduces energy intake and appetite by increasing satiety and decreasing hunger and food cravings. Animal studies show it can modulate fat utilisation through the GIP receptor, and in human adipocytes cultured in vitro it acts on GIP receptors to regulate glucose uptake and modulate lipid uptake and lipolysis; these adipocyte findings are animal and in vitro data.

In clinical trials, tirzepatide 5, 10 and 15 mg lowered HbA1c by 2.01, 2.24 and 2.30 percentage points versus 1.86 with semaglutide 1 mg in SURPASS-2 (PMID 34170647), and produced mean body-weight changes of -15.0%, -19.5% and -20.9% versus -3.1% with placebo in SURMOUNT-1 (PMID 35658024). These figures come from separate trials with different populations and should not be compared across trials. Cardiovascular and kidney outcome data are summarised under the SURPASS-CVOT entries below.

In SURMOUNT-5 (NEJM 2025, PMID 40353578; open-label phase 3b, 751 adults with obesity without diabetes), mean body-weight change at 72 weeks was -20.2% with tirzepatide (maximum tolerated dose 10 or 15 mg weekly) versus -13.7% with semaglutide (1.7 or 2.4 mg weekly). In SURMOUNT-1 (NEJM 2022, PMID 35658024) the 15 mg arm lost a mean 20.9% of body weight versus 3.1% with placebo. In SURPASS-CVOT (NEJM 2025, PMID 41406444) tirzepatide was non-inferior to dulaglutide for cardiovascular events (hazard ratio 0.92; 95.3% CI 0.83 to 1.01); superiority was not shown.

— Notable finding

Development history

The UK marketing authorisation holder for Mounjaro (tirzepatide) is Eli Lilly Nederland B.V. (UK SmPC on the emc).

UK authorisation. On 8 November 2023 the MHRA announced that it had authorised, via a national application route, a new indication for the diabetes medicine Mounjaro (tirzepatide) for weight loss and weight management in adults; Mounjaro was therefore already authorised in the UK for type 2 diabetes before that date. On 25 January 2024 the MHRA announced approval of the four-dose Mounjaro KwikPen, and the current UK SmPC for the Mounjaro KwikPen on the emc gives 25 January 2024 as its date of first authorisation (section 9); that date applies to the KwikPen presentation and is not the first UK authorisation of the medicine.

Trial programme. SURPASS-2 (Frias et al., NEJM 2021) compared tirzepatide 5, 10 and 15 mg weekly with semaglutide 1 mg weekly in type 2 diabetes. SURMOUNT-1 (Jastreboff et al., NEJM 2022) reported mean body-weight changes of -15.0%, -19.5% and -20.9% at 5, 10 and 15 mg over 72 weeks versus -3.1% with placebo. SURMOUNT-5 (Aronne et al., NEJM 2025), an open-label phase 3b trial in adults with obesity without diabetes, reported -20.2% with tirzepatide versus -13.7% with semaglutide over 72 weeks.

Outcome trials. SURPASS-CVOT has been completed and published (Nicholls et al., NEJM 2025;393(24):2409-2420, PMID 41406444): in 13,299 randomised adults with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was non-inferior to dulaglutide for the primary composite of cardiovascular death, myocardial infarction or stroke (hazard ratio 0.92, 95.3% confidence interval 0.83 to 1.01; P = 0.003 for non-inferiority; P = 0.09 for superiority), so superiority was not shown. A pre-specified exploratory kidney analysis of SURPASS-CVOT (Zoungas et al., Lancet Diabetes Endocrinol 2026, PMID 42114520) reported a lower risk of a composite kidney outcome with tirzepatide than with dulaglutide (hazard ratio 0.77, 95% CI 0.68 to 0.88). The SURMOUNT-MMO trial of morbidity and mortality in obesity (NCT05556512) was listed on ClinicalTrials.gov as active, not recruiting, with an estimated primary completion date of October 2027.

NHS guidance. NICE published TA924 (tirzepatide for type 2 diabetes) on 25 October 2023 and TA1026 (tirzepatide for managing overweight and obesity) on 23 December 2024; NICE guideline NG28 (updated February 2026) now names tirzepatide among options for early-onset type 2 diabetes. The criteria are summarised in the UK regulatory section.

Licensed dose regimens

The regimens below are summarised from the UK Summaries of Product Characteristics. They are not a dosing recommendation; follow your prescriber.

Licensed Tirzepatide dose regimens
IndicationRouteRegimenNote
Type 2 diabetes (Mounjaro, MHRA-licensed)Subcutaneous, once weeklyStart 2.5 mg once weekly for 4 weeks, then 5 mg once weekly; if needed, increase in 2.5 mg steps after a minimum of 4 weeks on the current dose. Adults: maintenance doses 5, 10 and 15 mg, maximum 15 mg once weekly. Children and adolescents aged 10 to under 18 years: maintenance doses 5 mg and 10 mg, maximum 10 mg once weeklyMounjaro SmPC section 4.2. No data in paediatric patients under 50 kg with a BMI below the 85th percentile; caution is advised when escalating to 10 mg in paediatric patients under 60 kg. When added to a sulphonylurea or insulin, a reduction in the dose of the sulphonylurea or insulin may be considered; metformin and SGLT2 inhibitors can be continued. NICE TA924 sets the criteria for NHS use in type 2 diabetes.
Weight management in adults (Mounjaro, MHRA-licensed)Subcutaneous, once weeklySame schedule as above: start 2.5 mg once weekly for 4 weeks, then 5 mg; increases in 2.5 mg steps after a minimum of 4 weeks on the current dose. Maintenance doses 5, 10 and 15 mg; maximum 15 mg once weeklyMounjaro SmPC section 4.2. Stopping rule: if patients have been unable to lose at least 5% of their initial body weight 6 months after titrating to the highest tolerated dose, a decision is required on whether to continue treatment. The SmPC does not license weight management under 18 years. In SURMOUNT-1 the 5, 10 and 15 mg arms had mean weight changes of -15.0%, -19.5% and -20.9% at 72 weeks. NICE TA1026 sets the criteria for NHS use in obesity.
Administration and missed doses (both indications)Subcutaneous injection into the abdomen or thigh, or into the back of the upper arm if another person gives the injectionOnce weekly, at any time of day, with or without meals. A missed dose can be given within 4 days; if more than 4 days late, skip it. The day of weekly dosing can be changed if the interval between doses is at least 3 daysMounjaro SmPC section 4.2. No dose adjustment is required for renal or hepatic impairment, but experience in severe disease and in end-stage renal disease is limited, so caution is advised.
Licensed regimens summarised from the UK Summaries of Product Characteristics. Not a dosing recommendation; follow your prescriber.

Reconstitution & storage

Summarised studies

Summarised research studies
YearModelOutcomeCitationSource
2021Adults with type 2 diabetes, open-label head-to-head phase 3 RCTHbA1c change -2.01/-2.24/-2.30 percentage points (5/10/15 mg) versus -1.86 with semaglutide 1 mg; weight difference -1.9/-3.6/-5.5 kg versus semaglutideFrias JP, Davies MJ, Rosenstock J, et al. N Engl J Med. 2021;385(6):503-515PMID 34170647
2022Adults with obesity or overweight with a complication, without diabetes, RCTMean weight change -15.0% (5 mg), -19.5% (10 mg) and -20.9% (15 mg) versus -3.1% with placebo at 72 weeksJastreboff AM, Aronne LJ, Ahmad NN, et al. N Engl J Med. 2022;387(3):205-216PMID 35658024
2025Adults with obesity without diabetes, open-label head-to-head phase 3b RCTWeight change -20.2% (95% CI -21.4 to -19.1) with tirzepatide versus -13.7% (-14.9 to -12.6) with semaglutide at 72 weeksAronne LJ, Horn DB, le Roux CW, et al. N Engl J Med. 2025;393(1):26-36PMID 40353578
2021Adults with type 2 diabetes inadequately controlled by diet and exercise alone, monotherapy versus placebo, RCTHbA1c change -1.87%/-1.89%/-2.07% (5/10/15 mg) versus +0.04% with placebo at 40 weeksRosenstock J, Wysham C, Frias JP, et al. Lancet. 2021;398(10295):143-155PMID 34186022
2025Adults with type 2 diabetes and atherosclerotic cardiovascular disease, active-comparator RCTPrimary composite hazard ratio 0.92 (95.3% CI 0.83 to 1.01) versus dulaglutide; non-inferiority met, superiority not shownNicholls SJ, Pavo I, Bhatt DL, et al. N Engl J Med. 2025;393(24):2409-2420PMID 41406444
2026Exploratory analysis of an active-comparator cardiovascular outcomes RCTComposite kidney outcome hazard ratio 0.77 (95% CI 0.68 to 0.88) versus dulaglutideZoungas S, D'Alessio D, Pavo I, et al. Lancet Diabetes Endocrinol. 2026;14(7):544-557PMID 42114520

Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2)

Frias JP, Davies MJ, Rosenstock J, et al. N Engl J Med. 2021;385(6):503-515 · 2021 · PMID 34170647

Open-label, 40-week phase 3 trial of tirzepatide 5, 10 and 15 mg weekly versus semaglutide 1 mg weekly in 1,879 adults with type 2 diabetes. HbA1c fell by 2.01, 2.24 and 2.30 percentage points with tirzepatide versus 1.86 with semaglutide, and the abstract reports that tirzepatide at all doses was non-inferior and superior to semaglutide. Body-weight reductions were greater with tirzepatide (estimated treatment differences of -1.9, -3.6 and -5.5 kg).

PubMed

Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)

Jastreboff AM, Aronne LJ, Ahmad NN, et al. N Engl J Med. 2022;387(3):205-216 · 2022 · PMID 35658024

Phase 3 double-blind trial of tirzepatide 5, 10 and 15 mg weekly versus placebo in 2,539 adults with a BMI of 30 or more, or 27 or more with a weight-related complication, excluding diabetes, over 72 weeks including a 20-week dose-escalation period. Mean body-weight changes were -15.0%, -19.5% and -20.9% with tirzepatide versus -3.1% with placebo.

PubMed

Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5)

Aronne LJ, Horn DB, le Roux CW, et al. N Engl J Med. 2025;393(1):26-36 · 2025 · PMID 40353578

Phase 3b, open-label trial of tirzepatide (maximum tolerated dose 10 or 15 mg weekly) versus semaglutide (maximum tolerated dose 1.7 or 2.4 mg weekly) in 751 adults with obesity without diabetes over 72 weeks. Mean body-weight change was -20.2% with tirzepatide versus -13.7% with semaglutide; mean waist circumference change was -18.4 cm versus -13.0 cm.

PubMed

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1)

Rosenstock J, Wysham C, Frias JP, et al. Lancet. 2021;398(10295):143-155 · 2021 · PMID 34186022

Double-blind, placebo-controlled phase 3 monotherapy trial in adults with type 2 diabetes inadequately controlled by diet and exercise alone who were naive to injectable diabetes therapy. At 40 weeks mean HbA1c fell by 1.87%, 1.89% and 2.07% with tirzepatide 5, 10 and 15 mg versus a rise of 0.04% with placebo; body weight fell by 7.0 to 9.5 kg with tirzepatide.

PubMed

Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes (SURPASS-CVOT)

Nicholls SJ, Pavo I, Bhatt DL, et al. N Engl J Med. 2025;393(24):2409-2420 · 2025 · PMID 41406444

Cardiovascular outcomes trial in 13,299 randomised adults with type 2 diabetes and atherosclerotic cardiovascular disease, comparing tirzepatide (up to 15 mg weekly) with dulaglutide 1.5 mg weekly over a median 4.0 years. The primary composite of cardiovascular death, myocardial infarction or stroke occurred in 801 patients (12.2%) on tirzepatide and 862 (13.1%) on dulaglutide (hazard ratio 0.92; 95.3% CI 0.83 to 1.01; P = 0.003 for non-inferiority; P = 0.09 for superiority). Tirzepatide was non-inferior to dulaglutide; superiority was not shown.

PubMed

A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial

Zoungas S, D'Alessio D, Pavo I, et al. Lancet Diabetes Endocrinol. 2026;14(7):544-557 · 2026 · PMID 42114520

Pre-specified exploratory analysis of SURPASS-CVOT. The primary composite kidney outcome (persistent macroalbuminuria, persistent eGFR reduction of 50% or more, end-stage kidney disease or death from kidney disease) occurred in 396 (6.0%) patients on tirzepatide and 498 (7.6%) on dulaglutide (hazard ratio 0.77; 95% CI 0.68 to 0.88). This is an exploratory comparison with dulaglutide rather than a dedicated kidney-outcomes trial.

PubMed

Safety profile

This section summarises the UK SmPC for Mounjaro KwikPen on the emc (section 4.8 unless stated). In 14 completed phase 3 studies, 15,169 adult patients were exposed to tirzepatide; the SmPC also reports weight-management, obstructive sleep apnoea, heart failure with preserved ejection fraction and SURPASS-CVOT data.

Gastrointestinal effects are the most frequent. Nausea and diarrhoea are very common. Vomiting, constipation and abdominal pain are common in the type 2 diabetes trials and very common in the weight-management trials and SURPASS-CVOT. In pooled placebo-controlled type 2 diabetes studies, nausea occurred in 12.2%, 15.4% and 18.3% of patients on 5, 10 and 15 mg versus 4.3% on placebo, and diarrhoea in 11.8%, 13.3% and 16.2% versus 8.9%. In pooled SURMOUNT-1 and SURMOUNT-2 weight-management studies, nausea occurred in 24.6%, 29.0% and 28.0% versus 8.5%, and diarrhoea in 18.7%, 20.8% and 22.5% versus 7.8%. In SURPASS-CVOT the SmPC reports nausea in 25.1%, diarrhoea in 24.9%, constipation in 12.8% and vomiting in 11.6%. The incidence of nausea, vomiting and diarrhoea was higher during the dose-escalation period and decreased over time.

Hypoglycaemia risk increases when tirzepatide is used with a sulphonylurea or insulin, and the SmPC says a reduction in the dose of the sulphonylurea or insulin may be considered. In phase 3 clinical studies 10 (0.2%) patients reported severe hypoglycaemia.

Pancreatitis. Acute pancreatitis is listed as uncommon. Section 4.4 states that tirzepatide has not been studied in patients with a history of pancreatitis and should be used with caution in them, that post-marketing reports include necrotising pancreatitis and reports with a fatal outcome, and that if pancreatitis is confirmed tirzepatide should not be restarted. Cholelithiasis is common in the weight-management trials and SURPASS-CVOT and uncommon in the type 2 diabetes trials.

Other SmPC warnings (section 4.4). Gastrointestinal effects can cause dehydration, which may lead to acute renal failure. Tirzepatide has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis, and should be used with caution in them. Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Cases of pulmonary aspiration have been reported in patients receiving GLP-1 receptor agonists who undergo general anaesthesia or deep sedation, so the risk of residual gastric content due to delayed gastric emptying should be considered before procedures. The KwikPen contains benzyl alcohol (5.4 mg per 0.6 ml dose), with a risk of metabolic acidosis in patients with hepatic or renal impairment. Hair loss was reported in 4.9% of patients on tirzepatide versus 1.0% on placebo in the weight-management studies.

Heart rate. Maximum mean increases in heart rate were 3 to 5 beats per minute in the type 2 diabetes studies and 6 beats per minute in SURPASS-CVOT; in the pooled weight-management studies (SURMOUNT-1, -2 and -3) the mean increase was 3 beats per minute.

Antibodies. 45.1% to 65.1% of treated patients developed treatment-emergent anti-drug antibodies; up to 3% and 2.3% had neutralising antibodies against tirzepatide activity at the GIP and GLP-1 receptors respectively. The SmPC reports no identified clinically significant effect on pharmacokinetics or effectiveness.

Thyroid. In a 2-year rat study tirzepatide caused an increase in thyroid C-cell tumours (adenomas and carcinomas) at all doses, and the SmPC (section 5.3) states that the human relevance of these findings is unknown. A 6-month study in rasH2 mice showed no C-cell hyperplasia or neoplasia. The UK SmPC section 4.3 lists hypersensitivity as the only contraindication; a contraindication and boxed warning for medullary thyroid carcinoma and MEN 2 appear in the US label, not in the UK SmPC.

Reported contraindications & cautions

  • Hypersensitivity to tirzepatide or any of the excipients (the only contraindication listed in SmPC section 4.3)
  • Pregnancy: should not be used during pregnancy and is not recommended in women of childbearing potential not using contraception; discontinue at least 1 month before a planned pregnancy because of the long half-life (SmPC section 4.6; a caution rather than a section 4.3 contraindication)
  • Breast-feeding: the current SmPC (section 4.6) reports tirzepatide in breast milk as undetectable to very low (<10 ng/ml) in a study of 11 women and states that tirzepatide could be considered for use during breast-feeding; it is not listed as a contraindication
  • History of pancreatitis: not studied, use with caution; if pancreatitis is confirmed, tirzepatide should not be restarted (SmPC section 4.4)
  • Severe gastrointestinal disease, including severe gastroparesis: not studied, use with caution (SmPC section 4.4)
  • Diabetic retinopathy: rapid improvement in glucose control has been associated with a temporary worsening (SmPC section 4.4)
  • Dehydration from gastrointestinal effects may lead to acute renal failure (SmPC section 4.4)
  • General anaesthesia or deep sedation: pulmonary aspiration has been reported with GLP-1 receptor agonists, so the risk of residual gastric content should be considered before procedures (SmPC section 4.4)
  • Medullary thyroid carcinoma or MEN 2: a contraindication and boxed warning in the US label, but not a contraindication in the UK SmPC (section 4.3 lists hypersensitivity only); thyroid C-cell tumours occurred in rats at all doses and the human relevance is unknown (SmPC section 5.3), so discuss any history with the prescriber

Known interactions (product label)

  • Sulphonylureas and insulin: increased hypoglycaemia risk; a reduction in the dose of the sulphonylurea or insulin may be considered (SmPC sections 4.2 and 4.4).
  • Oral medicines generally: tirzepatide delays gastric emptying, which can decrease Cmax and delay tmax of oral medicines; no dose adjustment is expected for most (SmPC section 4.5).
  • Narrow-therapeutic-index oral medicines (for example warfarin, digoxin): the SmPC recommends monitoring, especially at initiation and following dose increase (section 4.5).
  • Oral contraceptives: a single dose reduced oral contraceptive exposure, which is not considered clinically relevant, with no dose adjustment in women with a normal BMI. In women with obesity or overweight the SmPC advises switching to a non-oral contraceptive method, or adding a barrier method for 4 weeks after starting tirzepatide and for 4 weeks after each dose escalation (section 4.5).
  • Metabolism: tirzepatide is metabolised by proteolytic cleavage of the peptide backbone, beta-oxidation of the C20 fatty diacid moiety and amide hydrolysis (SmPC section 5.2).

UK regulatory status

Tirzepatide is licensed in the United Kingdom as Mounjaro, a prescription only medicine (UK SmPC for Mounjaro KwikPen on the emc). The emc lists the KwikPen in six strengths (2.5, 5, 7.5, 10, 12.5 and 15 mg); each pen contains 4 doses of 0.6 ml. Section 4.1 of the SmPC lists two indications: (1) treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise, as monotherapy when metformin is considered inappropriate due to intolerance or contraindications, or in addition to other medicinal products for the treatment of diabetes; and (2) weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial BMI of 30 kg/m2 or more (obesity), or 27 kg/m2 to under 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition. Section 5.1 also reports trial results in obstructive sleep apnoea and heart failure with preserved ejection fraction; these are not separate indications. Zepbound is the US brand name and is not a UK brand.

NICE guidance. TA924 (published 25 October 2023, last updated 1 September 2025) recommends tirzepatide for treating type 2 diabetes alongside diet and exercise in adults when it is insufficiently controlled only if triple therapy with metformin and 2 other oral antidiabetic drugs is ineffective, not tolerated or contraindicated and they have a BMI of 35 kg/m2 or more with specific psychological or other medical problems associated with obesity, or a BMI of less than 35 kg/m2 and insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related complications; the guidance sets out when a lower BMI threshold applies to some ethnic groups and requires the commercial arrangement. TA1026 (published 23 December 2024, last updated 1 September 2025) recommends tirzepatide as an option for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity in adults, only if they have an initial BMI of at least 35 kg/m2 (a lower threshold, usually reduced by 2.5 kg/m2, applies for people from some ethnic backgrounds) and at least 1 weight-related comorbidity and the company provides it according to the commercial arrangement; it refers to NHS England interim commissioning guidance setting out who may be eligible over a 3-year phased introduction. NICE guideline NG28 (updated 18 February 2026), recommendation 1.16.1, advises that for adults with early onset type 2 diabetes clinicians offer modified-release metformin and an SGLT-2 inhibitor and consider adding either a GLP-1 receptor agonist for its cardiovascular, renal and glycaemic benefits or tirzepatide for its glycaemic benefits.

Supply. Mounjaro is a prescription only medicine and is intended to be supplied on prescription. The MHRA has published a notice on falsified Mounjaro (24 February 2026, 'Falsified Mounjaro KwikPen 15mg pre-filled pens'). Tirzepatide sold as a research chemical is not the licensed product.

Tirzepatide is not on the WADA Prohibited List as of 2026.

Frequently asked questions

Is Zepbound available in the UK?
Zepbound is the US brand name for tirzepatide. In the UK, tirzepatide is supplied as Mounjaro (KwikPen), a prescription only medicine whose UK SmPC lists both type 2 diabetes and weight management as indications.
Are tirzepatide peptides sold as research chemicals the same as Mounjaro?
No. Tirzepatide is a licensed prescription only medicine in the UK (Mounjaro KwikPen is listed as a prescription only medicine on the emc), not an unlicensed research chemical. Bulk or lyophilised tirzepatide sold for research-only use is a separate channel and is not the licensed product; any clinical use of tirzepatide should use MHRA-authorised product through prescription.
Is tirzepatide better than semaglutide?
Two head-to-head trials compared them. In SURPASS-2 (type 2 diabetes, open-label, 40 weeks, n=1,879), HbA1c fell by 2.01, 2.24 and 2.30 percentage points with tirzepatide 5, 10 and 15 mg versus 1.86 with semaglutide 1 mg, and the estimated body-weight differences were -1.9, -3.6 and -5.5 kg. In SURMOUNT-5 (adults with obesity without diabetes, open-label, 72 weeks, n=751), mean weight change was -20.2% with tirzepatide (maximum tolerated dose 10 or 15 mg) versus -13.7% with semaglutide (1.7 or 2.4 mg). Which medicine suits an individual depends on their clinical circumstances and is for their prescriber to decide.
How does dual GIP and GLP-1 receptor agonism work?
Tirzepatide activates both the GIP and GLP-1 receptors (UK SmPC section 5.1). The SmPC states that it increases pancreatic beta-cell glucose sensitivity, enhances first- and second-phase insulin secretion in a glucose-dependent manner and delays gastric emptying (a delay that diminishes over time), and that clinical studies show reduced energy intake and appetite through increased satiety. GIP receptors are also present on adipocytes; the SmPC describes effects on fat utilisation and lipid handling from animal studies and cultured human adipocytes.
Is tirzepatide available on the NHS?
NICE TA924 recommends tirzepatide for type 2 diabetes in adults only in defined circumstances (after triple therapy with metformin and 2 other oral antidiabetic drugs is ineffective, not tolerated or contraindicated, plus BMI and other criteria). NICE TA1026 recommends tirzepatide for managing overweight and obesity only for adults with an initial BMI of at least 35 kg/m2 (usually 2.5 kg/m2 lower for people from some ethnic backgrounds) and at least 1 weight-related comorbidity, with a 3-year phased introduction set out in NHS England interim commissioning guidance. NICE guideline NG28 (updated February 2026) also names tirzepatide among options for adults with early onset type 2 diabetes. Eligibility is decided by the prescriber against the current guidance.
Does tirzepatide cause hypoglycaemia?
The SmPC reports that the risk of hypoglycaemia is increased when tirzepatide is used with a sulphonylurea or insulin, and that a reduction in the dose of the sulphonylurea or insulin may be considered. In phase 3 clinical studies, 10 (0.2%) patients reported severe hypoglycaemia.
What are the common side effects?
Gastrointestinal effects are the most frequent. Nausea and diarrhoea are very common; vomiting, constipation and abdominal pain are common in the type 2 diabetes trials and very common in the weight-management trials. In pooled type 2 diabetes studies nausea occurred in 12.2% to 18.3% of patients across 5, 10 and 15 mg versus 4.3% on placebo, and in pooled weight-management studies in 24.6% to 29.0% versus 8.5%. These effects were more frequent during dose escalation and decreased over time. Acute pancreatitis is listed as uncommon, with post-marketing reports of necrotising pancreatitis and cases with a fatal outcome; if pancreatitis is confirmed tirzepatide should not be restarted. Other SmPC-listed points include cholelithiasis, temporary worsening of diabetic retinopathy with rapid glucose improvement, hair loss in the weight-management studies, and mean heart-rate increases of 2 to 6 beats per minute depending on the study (UK SmPC sections 4.4 and 4.8).
What is the thyroid cancer warning?
In a 2-year rat study tirzepatide caused an increase in thyroid C-cell tumours at all doses; UK SmPC section 5.3 states that the human relevance is unknown. The US label carries a boxed warning and a contraindication for personal or family history of medullary thyroid carcinoma and for MEN 2. The UK SmPC (section 4.3) lists only hypersensitivity to the active substance or excipients as a contraindication and does not mention medullary thyroid carcinoma. Anyone with a personal or family history of thyroid cancer should discuss this with their prescriber.
Has tirzepatide been shown to protect the heart or kidneys?
SURPASS-CVOT (NEJM 2025, PMID 41406444; 13,299 adults with type 2 diabetes and atherosclerotic cardiovascular disease) compared tirzepatide with dulaglutide, not with placebo. Tirzepatide was non-inferior for the primary composite of cardiovascular death, myocardial infarction or stroke (hazard ratio 0.92; 95.3% CI 0.83 to 1.01), and superiority was not shown (P = 0.09). A pre-specified exploratory analysis found a lower risk of a composite kidney outcome versus dulaglutide (hazard ratio 0.77; 95% CI 0.68 to 0.88; Lancet Diabetes Endocrinol 2026, PMID 42114520). The SURMOUNT-MMO obesity morbidity and mortality trial (NCT05556512) was listed on ClinicalTrials.gov as active, not recruiting.
Does tirzepatide affect the contraceptive pill?
UK SmPC section 4.5 reports that a single dose of tirzepatide reduced oral contraceptive exposure, which was not considered clinically relevant, and that no dose adjustment is needed in women with a normal BMI. In women with obesity or overweight, the SmPC advises switching to a non-oral contraceptive method, or adding a barrier method of contraception for 4 weeks on starting tirzepatide and for 4 weeks after each dose escalation. Section 4.6 states tirzepatide should not be used during pregnancy and is not recommended in women of childbearing potential not using contraception.
Is tirzepatide a prescription-only medicine in the UK?
Yes. The emc product page for Mounjaro KwikPen lists it as a prescription only medicine, licensed for type 2 diabetes and for weight management.
Is tirzepatide prohibited in sport?
Tirzepatide is not on the WADA Prohibited List as of 2026.

References

  1. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). Frias JP, Davies MJ, Rosenstock J, et al. N Engl J Med. 2021;385(6):503-515 (2021). PMID 34170647
  2. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). Jastreboff AM, Aronne LJ, Ahmad NN, et al. N Engl J Med. 2022;387(3):205-216 (2022). PMID 35658024
  3. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). Aronne LJ, Horn DB, le Roux CW, et al. N Engl J Med. 2025;393(1):26-36 (2025). PMID 40353578
  4. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Rosenstock J, Wysham C, Frias JP, et al. Lancet. 2021;398(10295):143-155 (2021). PMID 34186022
  5. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes (SURPASS-CVOT). Nicholls SJ, Pavo I, Bhatt DL, et al. N Engl J Med. 2025;393(24):2409-2420 (2025). PMID 41406444
  6. A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial. Zoungas S, D'Alessio D, Pavo I, et al. Lancet Diabetes Endocrinol. 2026;14(7):544-557 (2026). PMID 42114520
  7. UK SmPC: Mounjaro KwikPen (tirzepatide) on the emc
  8. MHRA — Mounjaro authorised for weight management (8 November 2023)
  9. MHRA — Four-dose Mounjaro KwikPen approved (25 January 2024)
  10. NICE TA924 — Tirzepatide for treating type 2 diabetes
  11. NICE TA1026 — Tirzepatide for managing overweight and obesity
  12. NICE NG28 — Type 2 diabetes in adults: management
  13. Frias et al. 2021 — SURPASS-2 (PMID 34170647)
  14. Jastreboff et al. 2022 — SURMOUNT-1 (PMID 35658024)
  15. Aronne et al. 2025 — SURMOUNT-5 (PMID 40353578)
  16. Rosenstock et al. 2021 — SURPASS-1 (PMID 34186022)
  17. Nicholls et al. 2025 — SURPASS-CVOT (PMID 41406444)
  18. Zoungas et al. 2026 — SURPASS-CVOT kidney analysis (PMID 42114520)
  19. ClinicalTrials.gov — SURMOUNT-MMO (NCT05556512)

Appears in research stacks

Side-by-side comparisons

Cited in research summaries

Related peptides